文献速递甲状腺疾病

TRIAC治疗缓解甲状腺激素抵抗β型患者甲亢症状并降低T4、T3及代谢率

TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

回顾性队列研究纳入8例RTHβ成人患者,评估TRIAC治疗对甲亢症状、甲状腺激素、静息能量消耗及代谢参数的影响。TRIAC降低HSS评分、游离T4和总T3,静息能量消耗呈下降趋势但未达统计学显著,TSH、血脂、睡眠心率和NT-proBNP无变化,耐受良好。

要点

  • TRIAC可改善RTHβ患者甲亢症状并降低游离T4和总T3水平
  • TRIAC未升高TSH或加重肝脏激素抵抗及心脏甲状腺激素效应
  • TRIAC耐受良好,但静息能量消耗下降趋势未达统计学显著

核心结论

  • TRIAC治疗RTHβ可缓解甲亢症状并降低静息能量消耗和循环甲状腺激素水平,不加重肝脏激素抵抗或心脏甲状腺激素效应。
  • 未来需临床试验确定TRIAC是否改变该病的心血管不良结局。

研究设计与样本

  • 回顾性队列研究,纳入8例RTHβ成人患者(平均年龄41岁;4男4女),来自转诊中心。

主要发现

  • TRIAC耐受良好,无副作用。

临床怎么用

  • 对于RTHβ患者,TRIAC可作为一种治疗选择以缓解甲亢症状并降低甲状腺激素水平。
  • 治疗期间需监测甲状腺激素、TSH、血脂、心率和NT-proBNP等指标。

局限性

  • 回顾性研究,样本量小(8例)。
  • 静息能量消耗变化未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The treatment of resistance to thyroid hormone β (RTHβ) is challenging because features of hyperthyroidism in some tissues coexist with a hormone-resistant, hypothyroid state in other organs. OBJECTIVE: To determine whether triiodothyroacetic acid (TRIAC) therapy alleviates hyperthyroid symptoms and changes circulating thyroid hormones, resting energy expenditure and metabolic parameters in RTHβ. DESIGN: Retrospective cohort study. SETTING: Referral center. PARTICIPANTS: Eight adult patients with RTHβ (mean age 41 years; 4 males, 4 females). MAIN OUTCOME MEASURES: Hyperthyroid Symptom Scale (HSS) score, serum free T4 and total T3, resting energy expenditure, sleeping heart rate, fasting lipids, and glucose and systemic insulin resistance. RESULTS: From abnormally elevated levels prior to treatment, TRIAC therapy lowered HSS scores (baseline 17.5 vs posttreatment 6; P = .0014), showed a reduced resting energy expenditure trend (baseline Z-score +1.3 vs posttreatment +0.89; P = .38) and normalized circulating free T4 (baseline free T4 30 pmol/L vs posttreatment 17 pmol/L; P = .007) and total T3 (baseline 2.5 nmol/L vs posttreatment 1.4 nmol/L; P = .001) concentrations in 7 out of 8 patients, without any rise in their serum TSH (baseline 2.1 mU/L vs posttreatment 1.7 mU/L; P = .65), total cholesterol (baseline 4.9 mmol/L vs posttreatment 4.8 mmol/L; P = .81), and triglyceride (baseline 1.3 mmol/L vs post-treatment 1.3 mmol/L; P = .44). Their mean sleeping heart rate (baseline 60 bpm vs posttreatment 58 bpm; P = .56) and plasma N-terminal pro-brain natriuretic peptide (baseline 55 ng/L vs posttreatment 54 ng/L) were unchanged. TRIAC treatment was well tolerated, with no side effects. CONCLUSION: TRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Moran C, Martin-Grace J, Lyons G, et al. TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β. J Clin Endocrinol Metab. 2026. PMID: 41131705. doi:10.1210/clinem/dgaf583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。